Newron Pharmaceuticals

189 articles with Newron Pharmaceuticals

• Newron Presents Six-Month Interim Data From the First 100 Patients Randomized in Study 014/015 at the 31st European Congress of Psychiatry

  3/28/2023

  Newron Pharmaceuticals S.p.A. presented two e-posters at today’s “Schizophrenia and other psychotic disorders” session at the 31st European Congress of Psychiatry, taking place at the Palais des Congrès in Paris, France.

• Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia

  3/20/2023

  Newron Pharmaceuticals S.p.A. announces exciting topline results from Study 014, a phase II, international, randomized, open label, rater-blinded trial evaluating evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication.

• Newron to present at the 31st European Congress of Psychiatry

  3/17/2023

  Newron Pharmaceuticals S.p.A. announced that it will present two e-posters at the 31st European Congress of Psychiatry, taking place on 25-28 March 2023, at the Palais des Congrès of Paris - Place de la Porte Mailot in Paris, France.

• Newron Announces 2022 Financial Results and Provides Outlook For 2023

  3/14/2023

  Newron Pharmaceuticals S.p.A. today announced its financial results and operational highlights for the business year ended December 31, 2022, and provided an outlook for 2023.

• 

  Newron’s Schizophrenia Candidate Gets Better Over Time

  2/17/2023

  One-year data from a Phase II study of Newron's schizophrenia candidate evenamide showed sustained efficacy and continued improvements in symptoms of psychosis and disease severity.

• Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia

  2/16/2023

  Newron Pharmaceuticals S.p.A. announces very exciting new results from the first 100 randomized patients who have completed one year (52 weeks) of treatment in its international, randomized, open label, rater-blinded study of evenamide (study 014/015) as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication.

• Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia

  1/3/2023

  Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia.

• Newron provides H1 2022 results and updates on R&D and business activities

  9/15/2022

  Newron provides H1 2022 results and updates on R&D and business activities.

• Newron Extends Senior Management Team and Strengthens Commitment to ESG

  7/1/2022

  Newron Pharmaceuticals S.p.A. announced that it is extending its Senior Management team through the appointment of Filippo Moriggia to the newly created position of Vice President of Operations.

• Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology

  6/7/2022

  Interim results show improved symptoms of psychosis in patients with chronic TRS.

• Newron Announces 2021 Financial Results and Provides Outlook for 2022

  3/15/2022

  Newron Pharmaceuticals S.p.A. today announced its financial results and operational highlights for the year ended December 31, 2021, and provided an outlook for 2022.

• Newron Receives Fifth Tranche from Financing Agreement with European Investment Bank (EIB)

  10/18/2021

  Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announces that it has received Tranche 5 under its financing agreement with the European Investment Bank that was signed in October 2018 and comprises up to EUR 40 million, subject to achieving a set of agreed performance criteria.

• Newron Announces Half-Year 2021 Results

  9/16/2021

  Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced its operational highlights and financial results for the half-year ended June 30, 2021.

• Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia

  9/6/2021

  Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced the initiation of Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia.

• Newron Announces Paragraph IV ANDA Filings for Xadago® (safinamide) in the USA

  5/20/2021

  Newron Pharmaceuticals S.p.A. today announced that with reference to its media release of May 4, 2021, it received further Paragraph IV Notice Letters regarding the submission by a generic manufacturer of an Abbreviated New Drug Application to the U.S. Food and Drug Administration

• Newron Announces Paragraph IV ANDA Filing for Xadago® (safinamide) in the USA

  5/4/2021

  Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it received a Paragraph IV Notice Letter regarding the submission by a generic manufacturer of an Abbreviated New Drug Application

• Newron Announces Results of Explanatory Studies With Evenamide in Healthy Volunteers and Patients With Schizophrenia

  4/1/2021

  Primary objective of safety of evenamide met on all safety variables for study 010 in healthy volunteers and study 008 in patients with schizophrenia Additional safety and efficacy study 008A in therapeutic dose (30 mg BID) to start in April 2021

• 

  Clinical Catch-Up: March 15-19

  3/22/2021

  It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.

• Newron Announces 2020 Financial Results and Provides Outlook For 2021

  3/16/2021

  Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced its financial results and operational highlights for the year ended December 31, 2020, and provided an outlook for 2021.

• Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients

  3/15/2021

  Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients Global study to evaluate the reduction of levodopa-induced dyskinesia (PD LID) Targeting safinamide label extension for PD LID in key global markets